Despite the evidence showing that the accumulation of Th1 and Th17 cells promotes NASH, other studies suggest that dysregulation of lipid metabolism during NAFL and NASH causes a selective loss of CD4 T cells that leads to impaired anti-tumor surveillance in mouse models and human samples (68, 69). This evidence concerns the gene CD4 and metabolic dysfunction-associated steatohepatitis.